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Abstract 
Drugs have become an essential part of our lives due to their ability to improve people’s health and quality of life. 
However, for many diseases, approved drugs are not yet available or existing drugs have undesirable side effects, mak‑
ing the pharmaceutical industry strive to discover new drugs and active compounds. The development of drugs is an 
expensive process, which typically starts with the detection of candidate molecules (screening) after a protein target 
has been identified. To this end, the use of high‑performance screening techniques has become a critical issue in 
order to palliate the high costs. Therefore, the popularity of computer‑based screening (often called virtual screening 
or in silico screening) has rapidly increased during the last decade. A wide variety of Machine Learning (ML) tech‑
niques has been used in conjunction with chemical structure and physicochemical properties for screening purposes 
including (i) simple classifiers, (ii) ensemble methods, and more recently (iii) Multiple Classifier Systems (MCS). Here, 
we apply an MCS for virtual screening (D2‑MCS) using circular fingerprints. We applied our technique to a dataset 
of cannabinoid CB2 ligands obtained from the ChEMBL database. The HTS collection of Enamine (1,834,362 com‑
pounds), was virtually screened to identify 48,232 potential active molecules using D2‑MCS. Identified molecules were 
ranked to select 21 promising novel compounds for in vitro evaluation. Experimental validation confirmed six highly 
active hits (> 50% displacement at 10 µM and subsequent Ki determination) and an additional five medium active hits 
(> 25% displacement at 10 µM). Hence, D2‑MCS provided a hit rate of 29% for highly active compounds and an overall 
hit rate of 52%.
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Introduction
In silico (or computational) drug discovery relies on dif-
ferent computer-based techniques to find a novel or 
improved bio-active compound, which should exhibit a 
strong affinity to a particular target. Although in silico 
screening is present in the drug development process 
since the beginning of 90s [1, 2], its relevance has been 
progressively increasing until becoming an essential part 
of the drug-development process. This fact was mainly 
motivated by (i) a significant improvement in the perfor-
mance of computer systems, (ii) the introduction of novel 
algorithms and more expressive molecular descriptors, 
and (iii) the advent of large-scale public bioactivity data-
bases [3].
Limited processing capabilities of computer sys-
tems during the 90s led to in silico screening mainly 
focused on (i) building simple mathematical modelling 
approaches (often implemented as cellular automatons) 
for large-scale simulations of complex systems [4], (ii) the 
development of large scale databases enabling research-
ers to easily store and access the information [2], and (iii) 
the design of (affinity) fingerprints as novel descriptors 
for similarity searches in molecular databases and QSAR 
analyses [5]. As computers’ performance increased, 
the use of simple Machine Learning (ML) classification 
schemes for screening purposes became popular. Con-
cretely, the usage of support vector machines (SVM) [6, 
7], Decision Trees (DT) [8], Naïve Bayes [9], K-Nearest 
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Neighbors (KNN) [10], Artificial Neural Networks 
[11] and Self Organizing Maps (SOM) [12] were widely 
applied in the domain.
However, during the last decade the amount of public 
information available for screening has increased rap-
idly with the introduction of resources such as ChEMBL 
or PubChem [3, 13]. This fact had a negative impact on 
the performance of simple ML approaches due to their 
trend to build unstable classification models when han-
dling a high volume of information. In order to improve 
the predictive performance, ML models were equipped 
with multiple layers (stacking, deep learning) or identical 
ML algorithms were combined (ensemble of classifiers 
[14]). Specifically, Lenselink et  al. [15] demonstrate the 
suitability of using of Deep Neural Networks (DNN) [16] 
and Random Forests (RF) [17] methods against single ML 
models (such as Naïve Bayes or SVM) to predict the bio-
activity of molecules. Additionally, recent work [18, 19] 
applied several Boosting (such as AdaBoost or Multi-
Boost) and Fuzzy Forest approaches to predict (i) bio-
activity of molecules and (ii) toxicity of non-congeneric 
industrial chemicals, respectively.
The usage of above-mentioned ensembling methods 
contributed to significant performance improvements in 
the virtual screening domain. However, their introduc-
tion also brought about some important shortcomings 
such as: (i) the random selection of the information often 
used to build each inner classifier, (ii) the common usage 
of weak classifiers such as C4.5 or Decision Stumps to 
build up the classifier ensemble (although any ML clas-
sifier can be used) and, (iii) the impossibility combining 
different inner classifiers and configurations for them 
with concrete subsets of training information. These limi-
tations are implicit to the definition of ensemble classi-
fiers and are the key features to distinguish them against 
a great number of methods included in the Multiple 
Classifier Systems (MCS) [20] group. Wozniak et al. [20] 
revealed interesting features of MCS, including (i) their 
good performance when working in extreme situations 
such as scarcity of samples or information overload, (ii) 
their ability to outperform inner individual classifiers, 
(iii) the increase of the probability of finding an optimal 
model, and (iv) the reduction of the information (and 
hence the increase in the performance and speed) used 
to build each inner classifier. Keeping into account the 
above-mentioned issues we apply an MCS toolkit (called 
D2-MCS [21]) to increase the performance of virtual 
screening.
Methods
This section evaluates the suitability of using D2-MCS 
and its application in drug discovery domain. It also 
introduces the dataset and measures used to perform 
the experimental protocol. Finally, the methodology 
performed to carry out the virtual screening process is 
explained in detail.
Datasets
CB2 dataset
The data was gathered from ChEMBL version 22 
based on UniProt accession P34972 [3]. The activity 
data were filtered for potential duplicates, no activ-
ity or data validity comments were allowed, and only 
data from binding assays with a pChEMBL value was 
kept. This led to 3925 compounds. Subsequently, com-
pound fingerprints (FCFP_6) and physicochemical 
properties were calculated (see Additional file  1) [22]. 
No standardization was performed as the data was 
obtained from ChEMBL who include several curation 
steps before loading the molecules. The FCFP_6 finger-
prints properties were computed using the fingerprints 
to properties component from Pipeline Pilot Version 
2016.1.0 [23]; 2048 substructures/bits were selected 
based on their occurrence frequency in the data set 
[23]. A presence of 50% was the optimum frequency. 
Thereby, significant under- and over-representation 
were both avoided. In addition, Pipeline Pilot was also 
used to calculate the physicochemical properties [23]. 
Finally, the set was made into a binary classification 
set where the activity cut-off was set at a pChEMBL 
value > 7 for active compounds and written to a tab-
delimited text file using the InChiKey as unique identi-
fier [24]. The final set contained 1977 active compounds 
and 1948 inactive compounds (CB2Set, supporting 
information [25]). The obtained dataset includes 2133 
attributes (84 physicochemical properties, 2048 chemi-
cal-structure features and the activity class) to describe 
3925 compounds (instances). Table 1 shows the codifi-
cation of each feature grouped by type.
As can be observed from Table  1 each chemical sub-
structure is codified using a binary representation to 
indicate its presence (1) or absence (0) for each chemical 
compound. Additionally, the physicochemical descrip-
tors consist of continuous or discrete values depending 
on the descriptor type and metric representation.
Table 1 Feature characteristics and codification
Feature type Feature values No of features
Chemical substructure fingerprints Binary 2048
Physicochemical descriptors Discrete values 50
Continuous values 34
Total 2132
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Validation dataset
The high-throughput screening (HTS) set was down-
loaded from the Enamine website (containing 1,834,362 
compounds without class information). Molecules were 
standardized to make them compatible to ChEMBL 
data and encoded using the same feature representation 
as was used for the CB2 dataset (2048 chemical sub-
structure fingerprints and 84 physicochemical descrip-
tors). This set will be referred to as ValidationSet.
Evaluation measures
Quite a few performance measures for assessing the 
accuracy and rank of different classification approaches 
exist in the drug discovery domain. Concretely, we 
select Matthews Correlation Coefficient (MCC) [26, 
27] and the Positive Predictive Value (PPV) [28–30] 
measures due to their demonstrated ability to mini-
mize false negatives (FN) and false positives (FP) errors 
respectively.
MCC is a performance measure designed for binary 
classifiers that can be used in the case of imbalanced 
datasets (the distribution of instances in the classes is 
uneven). MCC can be easily computed from the val-
ues of the confusion matrix results (true positives or 
TP, true negatives or TN, false positives or FP and false 
negatives or FN) by using Eq. 1.
MCC is defined in the interval [− 1,1], where 1 stand 
for no classification errors, −1 means that all input 
instances were misclassified (inverse) and 0 reveals that 
the classification was absolutely uncorrelated with the 
real truth (random). As can be extrapolated from Eq. 1, 
achieving a balanced number of positive and negative 
classification hits is mandatory to obtain higher MCC 
values. Additionally, the inclusion of the four quantiles 
(TP, TN, FP and FN) in the MCC formula allows giv-
ing a better summary of the performance of classifica-
tion algorithms regarding other well-known metrics 
(such as Accuracy [31] or F1-Score [32]). The benefits 
of using MCC against other well-known measures com-
monly used to evaluate ML approaches in the health 
domain has been demonstrated by Chicco [33].
From another perspective, PPV is a well-known 
measure in the drug discovery domain due to its ability 
to assess the probability of having a positive outcome 
given a positive classification (also called a poste-
riori probability). Thus, PPV is an interesting meas-
ure since testing an inactive molecule (due to an FP 
error) is expensive [34]. The PPV can be computed by 
(1)
MCC
= TP × TN − FP × FN√
(TP + FP)× (FN + TN )× (FP + TN )× (TP + FN )
combining values included in the confusion matrix as 
defined by Eq. 2.
As could be noted, PPV is not able to accurately han-
dle most situations if used in isolation. In fact, a classifier 
could reach the maximum PPV score by identifying only 
one active molecule. With regard to this, over a balanced 
dataset where the probability of finding one active mol-
ecule is ½, a classifier could randomly select one instance 
to classify it as active and assign the inactive label to 
the remaining ones. This classifier could achieve a PPV 
score of one in half of the experiments (those which the 
instance classified as Active was really Active). Therefore, 
PPV needs to be accompanied by other performance 
indicators, such as MCC.
Modelling
To build our classification software we use D2-MCS due 
to its ability to easily build high-performance in silico 
screening models [21]. D2-MCS is an R-based toolkit that 
provides an efficient and flexible MCS mechanism that 
can be highly customized to ensure an adequate adapta-
tion to the intrinsic characteristics of the target dataset. 
Particularly, D2-MCS is able to handle high dimensional 
datasets by grouping the features of molecules (dataset 
columns) into several groups (called feature-clusters) 
according to user-defined criteria (i.e. type of chemical 
compounds, molecular weight, etc.). Then, for each fea-
ture-cluster, the toolkit is able to automatically determine 
the most suitable classifier (simple or ensemble) together 
with its best configuration. According to this informa-
tion, D2-MCS builds a set of classifiers (one per feature 
cluster) whose outputs will be combined to generate a 
single solution. The set of selected trained classifiers (one 
for each dataset part) together with a voting system com-
prises a whole D2-MCS instance. Figure 1 shows a global 
overview of the D2-MCS operation.
As shown in Fig. 1, D2-MCS operation is divided into 
three different stages. The first stage (called FEATURE 
CLUSTERING in Fig.  1) comprises the partitioning of 
training information based on a specific feature-cluster-
ing algorithm. Although D2-MCS provides by default 
several clustering methods (Fisher, Information Gain, 
etc.), it also allows users to define customized feature 
clustering methods in order to increase its compatibil-
ity regardless of the way of representing or encoding the 
information.
During the MCS BUILDING stage, for each split of the 
original dataset, D2-MCS is able to detect the most effec-
tive classifier (and its best configuration) from a wide 
(2)PPV = TP
TP + FP
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variety of ML techniques (up to 236 different classifiers 
from 47 families [35]). The best classifiers for each knowl-
edge partition together with their optimal configurations 
are compiled together to act as a set of individual experts 
whose outputs should be combined to generate a final 
result.
Then, the third stage (see SCREENING part in Fig. 1) 
is the screening of molecules by combining the outputs 
of the classifiers selected in the previous stage. To this 
end, D2-MCS implements two simple methods to com-
bine the outputs of inner classifiers and provides an API 
to easily define new output aggregator methods [21]. The 
implemented methods are: (i) a simple majority voting 
system where the final class is the one obtaining more 
than half of the votes and (ii) a weighted majority voting 
where the winner is the class achieving the highest over-
all value.
Probabilistic‑based ranking methodology
Due to the large number of molecules included in the 
validation dataset (1,834,362), the set of compounds clas-
sified as active by D2-MCS model will probably be large. 
A full in vitro evaluation of all these molecules is infeasi-
ble (costs, human resources, time). Hence, we designed 
a 3-stage probabilistic-based ranking method to select 
the most promising compounds from the ones receiving 
a positive classification. As can be seen in Fig. 2, the first 
stage is responsible for compiling the class probability of 
each compound tagged as Active (48,232) from all inner 
individual classifiers included in the Minimize FP model 
(a D2-MCS model comprising 3 classifiers for optimizing 
PPV and another one with 3 inner models for MCC). As 
can be depicted from stage 1 in Fig. 2, the achieved prob-
abilities are always greater than 0.5 since only compounds 
Fig. 1 Structure and functionality of the D2‑MCS toolkit. D2‑MCS builds a set of classifiers (one per feature cluster) whose outputs will be combined 
to generate a single solution. The set of selected trained classifiers (one for each dataset part) together with a voting system comprises a whole 
D2‑MCS instance
Fig. 2 Workflow of three‑stage potential candidate ranker 
methodology. Our ranking methodology comprised three main 
stages: (i) class probability estimator, (ii) global relevance calculator 
and (iii) relevance sorter
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previously labelled as Active (Active > 0.5, Inactive ≤ 0.5) 
were selected.
Once all probabilities are obtained, during the second 
stage we compute the global relevance (denoted as Θ in 
Fig. 2) of each candidate as a mathematical product of all 
its probabilities (see Eq. 3).
where numcluster stands form the number of clusters 
comprising the used meta-model.
Combining these probabilities using the product oper-
ator allows achieving a wide variety of output values (and 
thereby improves compatibility) even when individual 
input values are very close. As an example, given two vec-
tors of values [0.75, 0.75, 0.6], [0.6, 0.9, 0.6], the product 
operator ( Π ) is able to achieve 0.337 and 0.324 respec-
tively, while the summation ( Σ ) and the arithmetic mean 
( X¯ ) obtain the same values for both vectors (2.1 and 0.7 
respectively). Finally, the third stage entails the arrange-
ment of the chemical compounds by descendant accord-
ing to its global relevance value ( Θ ). This ensures that the 
best candidates are placed in the initial positions.
Chemical clustering
After virtual screening a further reduction of hits is 
required to ensure a chemically diverse set of prospec-
tive ligands for in vitro testing. Compounds identified as 
active by D2-MCS classifier were clustered based on the 
same binary features (FCFP_6) that were used for model 
training using the cluster molecules component in Pipe-
line Pilot version 2016 [23]. An average cluster popula-
tion of 20 was selected and the maximum Tanimoto 
distance between the cluster center and members was set 
at 0.35 (forcing a similarity of > 0.65 within clusters). This 
additional requirement increases the number of clus-
ters and thus leads to a lower number of compounds on 
average per cluster than the target average. However, the 
clusters resulting are chemically more conserved.
In vitro experimental techniques
Cell culture and membrane preparation
CHOK1hCB2_bgal cells (DiscoverRx, Fremont, CA, USA) 
were cultured in Dulbecco’s Modified Eagle’s Medium/
Nutrient Mixture F-12 Ham supplemented with 10% fetal 
calf serum, 1 mM glutamine, 50 µg/mL penicillin, 50 µg/
mL streptomycin, 300  mg/mL hygromycin and 800  µg/
mL geneticin in a humidified atmosphere at 37  °C and 
5%  CO2. Cells were subcultured twice a week at a ratio 
of 1:20 on 10-cm diameter plates by trypsinization. For 
(3)Θ =
numcluster∏
i=1
Ci
membrane preparation, the cells were subcultured with 
a ratio of 1:10 and transferred to 15-cm diameter plates. 
The cells were collected by scraping in 5 mL phosphate-
buffered saline (PBS) and centrifuged at 1000 g for 5 min. 
Pellets derived from 30 plates were combined and resus-
pended in 20  mL cold Tris–HCl,  MgCl2 buffer (50  mM 
Tris–HCl (pH 7.4), 5 mM  MgCl2). The cell suspension was 
homogenized using an UltraTurrax homogenizer (Hei-
dolph Instruments Schwabach, Germany). Membranes 
and cytosolic fractions were separated by centrifugation 
in a Beckman Optima LE-80 K ultracentrifuge (Beckman 
Coulter Inc., Fullerton, CA, USA) at 100,000 g for 20 min 
at 4  °C. The supernatant was discarded. The pellet was 
resuspended in 10  mL cold Tris–HCl,  MgCl2 buffer and 
homogenization and centrifugation steps were repeated. 
The membranes were resuspended in 10  mL cold Tris–
HCl,  MgCl2 buffer. Aliquots of 50 µL were stored at -80 °C 
until further use. The protein concentration was deter-
mined using the Pierce™ BCA Protein Assay Kit (Ther-
moFisher Scientific, Waltham, MA, USA).
[3H]CP55940 Displacement assay
[3H]CP55940 displacement assays on 96-well plates 
were performed in 50  mM Tris–HCl (pH 7.4), 5  mM 
MgCl2, and 0.1% BSA assay buffer. Membrane aliquots 
of CHOK1CB2_bgal containing 1.5  µg membrane pro-
tein were incubated at 25  °C for 2  h in the presence 
of ~ 1.5  nM [3H]CP55940 (specific activity 149  Ci/
mmol; PerkinElmer, Waltham, MA). At first, all com-
pounds were tested at a final concentration of 10  µM. 
When radioligand displacement was greater than 50%, 
full curves were recorded to determine the affinity (pKi) 
values of the compounds. Six different concentrations of 
the compounds were added by an HP D300 digital dis-
penser (Tecan Group Ltd, Männedorf, Switzerland). In 
order to determine the total binding, a control without 
test compound was included. Nonspecific binding was 
determined in the presence of 10 µM AM630. The total 
assay volume was 100 µL. The final concentration of 
DMSO was ≤ 0.25%. The incubation was terminated by 
rapid vacuum filtration through GF/C 96-well filter plates 
(PerkinElmer, Waltham, MA), to separate the bound and 
free radioligand, using a PerkinElmer Filtermate-har-
vester (PerkinElmer, Groningen, The Netherlands). Filters 
were subsequently washed twenty times with ice-cold 
assay buffer. The filter-bound radioactivity was deter-
mined by scintillation spectrometry using a  Microbeta2® 
2450 microplate counter (PerkinElmer, Boston, MA), 
after addition of 25 μl MicroScint 20 (PerkinElmer, Gron-
ingen, The Netherlands) and 3 h incubation.
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Data analysis
All experimental data were analyzed using GraphPad 
Prism 7 [36]. The data were normalized to percentage 
specific radioligand binding, where the total binding is 
100% and nonspecific binding is 0%. Nonlinear regres-
sion for one-site was used to determine the  IC50 values 
from the full curve  [3H]CP55940 displacement assays. 
The pKi values were obtained using Eq.  4 proposed by 
Cheng-Prusoff [37].
where [L] is the exact concentration  [3H]CP55940 deter-
mined per experiment and the  KD is the dissociation con-
stant of  [3H]CP55940, which is 1.24 nM as determined by 
Soethoudt et al. [37]. All data were obtained from three 
separate experiments performed in duplicate.
Results
This section presents the performance achieved by our 
method. To this end, we describe the D2-MCS configu-
ration parameters used to generate the models. Then 
potential screening candidates were identified by execut-
ing the previous models over the Validation set. Con-
secutively, the screening candidates were ranked by 
executing our probabilistic-based ranking methodology. 
Finally, in vitro analysis was performed over the selected 
candidates to determine their real activity.
D2‑MCS configuration
In order to execute our experimentation, the data-
set instances (rows) were randomly divided into four 
homogeneous and evenly sized groups. Figure 3 repre-
sents the configuration of groups and their usage for: 
(i) executing feature clustering, (ii) building, optimiz-
ing and evaluating inner classifiers and (iii) execute a 
screening task for benchmark the whole D2-MCS.
(4)Ki =
IC50(
1+
(
[L]
KD
))
As shown in Fig.  3, the first two groups were used 
to select an appropriate number of feature-clusters for 
D2-MCS. Then, the second and third groups were used 
to build the D2-MCS model (select the most appropri-
ate classifier for each dataset partition, build classifiers, 
and optimize their configurations). Finally, the fourth 
group has been reserved to assess the performance of 
the final model.
As previously stated, during the first stage of D2-MCS 
process (see Fig. 1) the original dataset is divided into 
several groups of non-repeated features. Although the 
latest version D2-MCS provides several feature-clus-
tering algorithms, we used the same clustering method 
as used in [21] (called MultiTypeFisherClustering) 
due to the good results achieved in this domain. Con-
cretely, the experimentation carried out in [21] demon-
strated the suitability of dividing the features into three 
clusters.
Once the best clustering configuration is obtained 
(three clusters), the D2-MCS building stage is executed. 
In detail, this stage is responsible for determining the 
best ML models (and parameter configuration) for 
each cluster. Additionally, D2-MCS allows defining an 
objective function to customize the model parameter-
optimization process. To follow the same criterion as 
previously commented, we use both PPV and MCC 
measures, which entails the generation of two different 
D2-MCS models (PPV-based and MCC-based).
Subsequently, in order to test the final performance 
both obtained models (PPV-based and MCC-based) 
were executed over the remaining dataset (see Group 
4 in Fig. 1) composed by 982 instances (504 active and 
478 inactive compounds). To compute the final class 
of each compound, the outputs of the inner classifiers 
included in each D2-MCS model are combined using a 
voting scheme where a compound is classified as Active 
whenever the number of positive outputs of each inner 
classifier is greater or equal than the negative ones. 
Conversely, the compound is classified as Inactive.
Fig. 3 CB2 dataset partitioning. The CB2 dataset instances (rows) were randomly divided into four homogeneous and evenly sized groups
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Following the same evaluation criteria used during the 
optimization stage, classification performance achieved 
in MCC (Fig.  4a) and PPV (Fig.  4b) scenarios were 
assessed using the same metric (MCC and PPV respec-
tively). For each experimental configuration, we plotted 
a horizontal double arrow representing the final perfor-
mance achieved during the test of the D2-MCS classifier. 
Additionally, for each cluster, we represent (as points) the 
performance achieved by the best classifier during the 
optimization/training stage. The graphical representa-
tion of D2-MCS performance (testing stage) also includes 
the numeric value represented (P) and the achieved con-
fusion matrix (TP, TN, FP, and FN). Furthermore, the 
information about the best classifier for each cluster 
(optimization/training stage) specifies the numeric value 
represented (P) and the (greatest) classifier name (C).
As shown in Fig.  4a, the performance achieved dur-
ing the test stage slightly outperforms the individual 
outcomes obtained during the optimization stage. Addi-
tionally, the use of the MCC measure allows achieving a 
balanced number of misclassification errors (FP ≈ FN). 
Furthermore, from Fig. 4b it is easy to realize that using 
PPV as an objective function reduces the number of FP 
errors at expenses of increasing FN errors. Moreover, 
the D2-MCS classifier achieved better performance than 
simple ML models (see Additional file 2).
Additionally, after performing a global overview of 
Fig.  4 it can be conclude that: (i) D2-MCS can be used 
to build suitable measure-guided knowledge-generaliza-
tion models, and (ii) it is important to use an adequate 
domain-oriented measure in order to minimize the num-
ber of misclassification errors. In fact, as can be seen 
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C=ranger
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a MCC achieved during training stage MCC achieved during test stage
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Fig. 4 Performance comparison plot for testing stage (represented as a double arrow). a Indicates the performance obtained using the MCC 
measure and b shows the performance obtained using the PPV measure. Also shown (represented as dots) the name of classifier achieving the best 
performance for each cluster (C) together with its performance value during the optimization/training stage (P)
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in Fig.  4, MCC based models achieve fewer error rates 
than the PPV measure (113 and 132 errors respectively). 
Despite this, the results are quite promising (the rate of 
correctly classified compounds is very high), although 
we are aware that can be increased even more by taking 
advantage of the intrinsic characteristics of D2-MCS.
In order to demonstrate this hypothesis, we generate 
two meta-models by combining the predictions achieved 
by the D2-MCS models trained using MCC and PPV 
measures (see Minimize FP and Minimize FN in Fig. 5). 
Concretely, Minimize FP is responsible for labeling the 
target compound as Active whenever is predicted as 
‘Active’ by both D2-MCS models (PPV and MCC) while 
Minimize FN identifies the target compound as Active 
only if one of the D2-MCS models (PPV and MCC) pre-
dicts the compound as ‘Active’. For comparison purposes, 
both meta-models were executed over the same test-
ing dataset (see Group 4 in Fig.  3) as used by primitive 
D2-MCS models (PPV-based and MCC-based).
As can be seen in Fig.  5, both meta-models clearly 
improve the performance achieved by the primitive 
D2-MCS models. Focusing on the first approximation 
(Minimize FP), the performance is increased up to 21.3% 
(MCC) and 8.5% (PPV) regarding the original models 
optimized for MCC and PPV respectively. On the other 
hand, the second meta-model outperforms up to 7.9% 
(MCC) but decreases 2.9% (PPV) compared to the cor-
responding primitive models. The first approximation 
seems the most suitable alternative (best values of MCC, 
Accuracy, and PPV. The main reason for this circum-
stance can be easily explained through the confusion 
matrix described in Table 2.
As can be seen in Table 2, the number of overall errors 
achieved by second approximation is bigger than Mini-
mize FP (84 vs 33 respectively). Considering that Accu-
racy computes the overall probability of performing a 
correct classification, it is easy to conclude that the low 
rate of misclassification errors motivates the good Accu-
racy level achieved by first approximation.
Additionally, as can be realized from Table 2, the ability 
to avoid discarding potential Active compounds makes 
Minimize FN an adequate alternative for the research 
domain (where discovering the whole spectrum of poten-
tial candidate drugs is more important than minimizing 
trial costs). Conversely, the Minimize FP approximation 
achieves a significant reduction of FP errors (up to 95%) 
when compared with Minimize FP. This fact makes Mini-
mize FP a suitable approximation for the pharmaceuti-
cal industry where minimizing unnecessary trial tests 
(reduce costs) is more important than losing potential 
Active candidates.
Virtual screening
We applied our D2-MCS models in virtual screening 
prospectively. Here, we do not know the activities of the 
compounds screened a priori. Virtual screening refers to 
the use of computational approaches to identify chemi-
cal structures that are predicted to have particular prop-
erties. To this end, we analyzed the behavior of both 
meta-models (Minimize FP and Minimize FN) in a real-
istic scenario. We classified a list of chemical compounds 
included in the ValidationSet in order to determine 
their activity. Below, Table  4 summarizes the outcomes 
achieved by each model grouped by activity (Active or 
Inactive). As can be depicted for Table 4, the number of 
Active compounds predicted by Minimize FN is higher 
than Minimize FP (representing 9.085% and 2.629% of 
the whole dataset), while Minimize FP was able to classify 
more compounds as Inactive.
This scenario clearly fits the behavior described in 
Table 3, where Minimize FP trends to reduce the FP rate 
despite sacrificing potential Active compounds while 
Fig. 5 Performance comparison achieved for Minimize FP and 
Minimize FN meta‑models
Table 2 Confusion matrix achieved for both configurations
TP FP TN FN
Minimize FP 474 3 475 30
Minimize FN 480 60 418 24
Table 3 Summary of predictions group by model
Meta‑models Predictions
Minimize FP Minimize FN
48,232 166,664 Active
1,786,130 1,667,698 Inactive
1,834,362 1,834,362 Total
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Minimize FN is focused on exploring all the potential 
candidate compounds at expenses of increasing the num-
ber of unnecessary trials (caused by FP errors).
The high amount of potential Active components 
(48,232) makes it unfeasible (in terms of human resources 
and trial cost) to perform an evaluation of all the pre-
dicted actives. Therefore, we selected the most promising 
candidates for experimental validation from the com-
pounds classified as Active by Minimize FP. We address 
the importance of using an adequate candidate-selection 
method when dealing with a reduced set of compounds 
(representing only 0.083% of the potential candidates) to 
avoid obtaining unrepresentative information. To prevent 
random selection of candidates, we combined a chemi-
cal clustering method with a probabilistic-based ranking 
methodology. The designed probabilistic-based rank-
ing methodology was used to rank each active-predicted 
compound (see Additional file 3). This ranking was sub-
sequently used to select the most suitable candidates 
from chemical clusters. These clusters were constituted 
from the list of 48,232 predicted actives. Clustering of 
the predicted actives resulted in 28,217 chemical clusters. 
From each cluster, the top scoring member (based on the 
ranks generated by the probabilistic-based ranking meth-
odology) was kept while the other cluster members were 
discarded. Using this rank, 21 novel and diverse com-
pounds were purchased. The average distance in the set 
based on Tanimoto distance was 0.81 ± 0.11, the average 
probability to be active was 0.77 ± 0.02, and the average 
distance to the training set was 0.26 ± 0.06. Hence, it can 
be concluded that the set selected was internally chemi-
cally diverse, highly probable to be active, and relatively 
close to the training set.
In vitro evaluation
The affinities of the 21 purchased compounds for the 
human CB2 receptor were determined in a radioligand 
displacement assay using  [3H]CP55940 as the radiola-
beled competitor (Table  4). Six compounds were able 
to displace more than 50% of the radioligand at 10 uM, 
and were thus further characterized for their affin-
ity, where the compound with the highest affinity was 
Z336532434 (pKi 7.67). Moreover, 5 more compounds 
were able to displace > 25% of the radioligand and are 
considered medium hits. Taken together, we were able 
to obtain 11 hits from the 21 novel compounds (rep-
resenting a 52% hit rate). As can be seen from Table 4, 
four out of these 11 are in the top five based on proba-
bility. Moreover, the top 10 compounds based on prob-
ability contained 7 out of 11 actives. We conclude that 
our defined probability can be a good estimator of bio-
logical activity. Most notable is compound Z27680708, 
which was measured to have a pKi of 7.46 while the 
Tanimoto distance to the training set was one of the 
largest at 0.31.
Conclusions
This work uses Multiple Classifier Systems (MCS) in 
early preclinical drug discovery. Concretely, we apply 
D2-MCS over a training dataset to build two measure-
guided D2-MCS models (PPV and MCC). Furthermore, 
two meta-models (Minimize FP and Minimize FN) were 
generated by combining the predictions achieved by the 
previous D2-MCS models.
Results achieved by both meta-models show the suit-
ability of using Minimize FP due to its ability to avoid FP 
errors (only 3 from 477). To this end, we execute Mini-
mize FP over a validation dataset (comprised of 1,834,62 
compounds) together with our probabilistic-based rank-
ing methodology to obtain the 21 most promising active 
compounds.
We have demonstrated that an appropriate combina-
tion of D2-MCS models can be successfully used for 
virtual screening (to predict the biological activity of 
chemical structures). The identified hits were chemically 
diverse while similar to the training set. We were success-
fully able to determine a probability of biological activity, 
which demonstrated a predictive performance for bio-
logical activity.
Despite the promising results achieved here (being a 
52% hit rate), further improvements should be addressed 
to increase the classification performance. Therefore, 
future work should be focused on two main aspects 
(i) dataset processing and (ii) the improvement of the 
D2-MCS toolkit. Regarding data quality, the detection, 
and removal of irrelevant, noisy, or valueless features 
from the input dataset should be considered. Moreover, 
to increase the performance of D2-MCS new and effi-
cient feature clustering methods should be implemented.
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Table 4 Experimentally validated compounds
Data image IDnumber/
InChiKey
Probability Distance
To closest
pKi ± SEM
or
 % displ.
Z336532434
/
MQIUMQLPFGFWME-UHFFFAOYSA-N
0.82 0.32 7.67 ± 0.17
Z28609248
/
HXJYJTXXUOYRSB‑UHFFFAOYSA‑N
0.81 0.29 16%
Z26476746
/
VYCWCTZNPBMJFW-UHFFFAOYSA-N
0.80 0.21 6.54 ± 0.14
Z91179667
/
XGVYRTRSINEVTE-UHFFFAOYSA-N
0.78 0.15 29%
Z32934509
/
OLTBRCMQFCQBIR-UHFFFAOYSA-N
0.78 0.28 6.47 ± 0.02
Z28357657
/
NPRYSOPFJOGFSA-UHFFFAOYSA-N
0.78 0.34 6.81 ± 0.29
Z30007452
/
VBFKBSAAMKINJD‑UHFFFAOYSA‑N
0.77 0.24 − 2%
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Table 4 (continued)
Data image IDnumber/
InChiKey
Probability Distance
To closest
pKi ± SEM
or
 % displ.
Z27687312
/
IHBHBQAPEZJCNM-UHFFFAOYSA-N
0.77 0.23 7.22 ± 0.46
Z46091805
/
QKQCBVJKUBSZOR-UHFFFAOYSA-N
0.76 0.24 38%
Z27687279
/
WTGACPGXOMAZFA-UHFFFAOYSA-N
0.76 0.22 38%
Z44866691
/
WPWBUEOMELTWOC‑FCDQGJHFSA‑N
0.76 0.25 − 1%
Z28357392
/
VBIMVPWQQQESTK-UHFFFAOYSA-N
0.76 0.13 26%
Z1317886912
/
MEXULSRPIBCDQX‑UHFFFAOYSA‑N
0.76 0.28 3%
Z44867007
/
PCCXRCZRXNECAZ‑JLPGSUDCSA‑N
0.76 0.30 0%
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Table 4 (continued)
Data image IDnumber/
InChiKey
Probability Distance
To closest
pKi ± SEM
or
 % displ.
Z237484560
/
LIGIHTRZFDFDAN‑UHFFFAOYSA‑N
0.75 0.15 − 1%
Z223843850
/
CVSSLUCDGJDGHX‑UHFFFAOYSA‑N
0.75 0.32 − 5%
Z27019562
/
WNXCAGCQOBOQMO-UHFFFAOYSA-N
0.75 0.33 30%
Z55473655
/
VDTRQSFAESBVFB‑UHFFFAOYSA‑N
0.75 0.26 7%
Z2094674960
/
RISCNDGLDMULEE‑UHFFFAOYSA‑N
0.75 0.29 0%
Z1523102560
/
IXASXIGZGJSBJT‑UHFFFAOYSA‑N
0.75 0.30 18%
Z27680708
/
HKWXDCJIBMAAFV-UHFFFAOYSA-N
0.74 0.31 7.46 ± 0.32
Shown are the structure, enamine identifier (ID number), InChIKey, assigned probability, distance to the training set, and biological activity. Biological activity is shown 
as pKi (with a standard error of the mean) when available or  % displacement of the radioligand by 10 μM of the compound. Identified novel hits are indicated in italic
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